- Home
- VCIG vs APVO Comparison
VCIG vs APVO Comparison
Compare VCIG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- APVO
- Stock Information
- Founded
- VCIG 2013
- APVO 2016
- Country
- VCIG Malaysia
- APVO United States
- Employees
- VCIG N/A
- APVO N/A
- Industry
- VCIG Diversified Commercial Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- APVO Health Care
- Exchange
- VCIG Nasdaq
- APVO Nasdaq
- Market Cap
- VCIG 22.5M
- APVO 21.7M
- IPO Year
- VCIG 2023
- APVO N/A
- Fundamental
- Price
- VCIG $3.19
- APVO $1.42
- Analyst Decision
- VCIG
- APVO
- Analyst Count
- VCIG 0
- APVO 0
- Target Price
- VCIG N/A
- APVO N/A
- AVG Volume (30 Days)
- VCIG 894.4K
- APVO 4.4M
- Earning Date
- VCIG 10-06-2025
- APVO 11-10-2025
- Dividend Yield
- VCIG N/A
- APVO N/A
- EPS Growth
- VCIG N/A
- APVO N/A
- EPS
- VCIG 5.34
- APVO N/A
- Revenue
- VCIG $32,903,041.00
- APVO N/A
- Revenue This Year
- VCIG N/A
- APVO N/A
- Revenue Next Year
- VCIG N/A
- APVO N/A
- P/E Ratio
- VCIG $0.36
- APVO N/A
- Revenue Growth
- VCIG 24.77
- APVO N/A
- 52 Week Low
- VCIG $1.73
- APVO $1.32
- 52 Week High
- VCIG $4,644.00
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- VCIG 47.97
- APVO 39.46
- Support Level
- VCIG $1.75
- APVO $1.48
- Resistance Level
- VCIG $3.49
- APVO $1.57
- Average True Range (ATR)
- VCIG 0.53
- APVO 0.07
- MACD
- VCIG -0.10
- APVO -0.01
- Stochastic Oscillator
- VCIG 58.67
- APVO 0.19
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.